Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CA9 | Q16790 | 6/20 | 0.45 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17231312 | 1.00 | LMNA (0.60) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL19767509 | 1.00 | LMNA (0.60) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL15344529 | 1.00 | LMNA (0.60) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL15344523 | 1.00 | LMNA (0.60) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL15333945 | 1.00 | LMNA (0.60) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL23046595 | 1.00 | LMNA (0.60) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL18710677 | 1.00 | LMNA (0.60) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL16882358 | 1.00 | LMNA (0.60) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL22511639 | 0.91 | LMNA (0.59) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL18710675 | 0.90 | LMNA (0.50) | LMNAKMT2APOLBALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105158-A1 | BIS(BENZYLISOQUINOLINE) ALKALOIDS AS TLR4 AGONIST | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2026-05-21 | — | — | WO | disclosed |
| CN-120305291-A | Function regulator based on sheep neutrophil release extracellular trapping net and application thereof | 佛山大学 | 2025-07-15 | — | — | CN | disclosed |
| US-20240390290-A1 | ISO-OSMOTIC AND NEAR ISO-OSMOTIC OXYGEN THERAPEUTIC FORMULATIONS AND METHODS THEREOF | NUVOX PHARMA LLC (US) | 2024-11-28 | — | — | US | disclosed |
| WO-2024173283-A1 | MACROENCAPSULATION DEVICES INCLUDING IMMUNOMODULATORY COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240207216-A1 | COMPOSITIONS AND METHOD FOR TREATING GUT PERMEABILITY CAUSED BY HYDROGEN SULFIDE PRODUCING BACTERIA | THE DEPARTMENT OF VETERANS AFFAIRS | 2024-06-27 | — | — | US | disclosed |
| CN-117682956-A | Diterpenoid epimer derived from fructus zizyphi and preparation method and application thereof | 宿州绿源中医药科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-3426677-B1 | USE OF PNEUMOLYSIN PEPTIDES AS ANTAGONISTS AGAINST TOLL-LIKE RECEPTOR 4 AND METHODS OF TREATING TOLL-LIKE RECEPTOR 4 RELATED DISEASES | KEMYTH BIOTECH CO LTD (TW) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022190064-A1 | METHODS FOR IDENTIFYING SUBJECTS WITH BETACORONAVIRUS INFECTIONS WHO ARE AT RISK OF ACUTE RESPIRATORY SYNDROME AND METHODS FOR THE TREATMENT OF SAME | VEXO PHARMACEUTICALS DMCC (AE) | 2022-09-15 | — | — | WO | disclosed |
| CN-109071614-B | Pneumolysin PLY truncated peptide and application thereof | 碁米库斯生物科技股份有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-20220233570-A1 | TREATMENT OF ISCHEMIC STROKE WITH APTAMERS TARGETING TLR-4 | APTATARGETS, S.L. (ES) | 2022-07-28 | — | — | US | disclosed |
| US-20220233572-A1 | TREATMENT OF TLR-4 MEDIATED DISEASES AND CONDITIONS WITH APTAMERS TARGETING TLR-4 | APTATARGETS, S.L. (ES) | 2022-07-28 | — | — | US | disclosed |
| EP-3969011-A1 | TREATMENT OF TLR-4 MEDIATED DISEASES AND CONDITIONS WITH APTAMERS TARGETING TLR-4 | Aptatargets, S.L. (ES) | 2022-03-23 | — | — | EP | disclosed |
| US-20220023325-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2022-01-27 | — | — | US | disclosed |
| CN-113966220-A | Treatment of TLR-4 mediated diseases and conditions with aptamers targeting TLR-4 | 奥普塔目标公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023325-A1 | SPECIFIC TLR4 ANTAGONIST IN THE TREATMENT OF MULTIPLE MYELOMA | TLR4, TLR3, TLR2 | LMNA 2057/4885KMT2A 574/4885POLB 4797/4885 |
| US-20220233572-A1 | TREATMENT OF TLR-4 MEDIATED DISEASES AND CONDITIONS WITH APTAMERS TARGETING TLR-4 | TLR9, TLR4, TLR3 | LMNA 1595/4885KMT2A 334/4885POLB 1853/4885 |
| US-20220233570-A1 | TREATMENT OF ISCHEMIC STROKE WITH APTAMERS TARGETING TLR-4 | TLR9, TLR3, TLR4 | LMNA 2701/4885KMT2A 678/4885POLB 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.